Overview.
Overview.At Shift Bioscience, our mission is to increase both healthspan and lifespan.
Shift’s leading target ID platform has identified an anti-fibrotic siRNA therapeutic for cell rejuvenation, providing a straightforward regulatory path to clinical proof of concept, with first in class opportunities in liver fibrosis and expansion potential to secondary fibrosis.
Shift has discovered hundreds of novel aging targets including those linked to disease states.
Shift Bioscience was founded by Dr Daniel Ives, CEO, and Dr Brendan Swain, CSO, with a wet lab in Cambridge (UK), computational group in Toronto (CA) and Boston (US) foothold for liver siRNA development and corporate leadership.
Leadership.
Investors.
